Chemotherapy-induced histologic changes in Wilms' tumors.

The nephrectomy specimens of 21 patients with Wilms' tumor who received preoperative chemotherapy consisting of vincristine and actinomycin D, alone or in combination, were studied pathologically; 1 patient also received radiation therapy. Pathological material from 20 randomly selected patients with Wilms' tumor who did not receive preoperative chemotherapy was reviewed and used as a control. Twenty tumors were of favorable histology, and one was unfavorable; all control tumors were of favorable histology.

Renal cell carcinoma in children.

Data from four pediatric hospitals concerning 20 children treated for renal cell carcinoma (RCC) from 1964-1978 were reviewed. Median age of the patients (pts) was 11.8 years (range, 14 months-19 years).

Clinical aspects of the rhabdoid tumor of the kidney: a report of the National Wilms' Tumor Study Group.

Rhabdoid tumor of the kidney (RTK), originally described as a monophasic sarcomatous variant of Wilms' tumor, is now recognized as a highly malignant, non-Wilms' tumor possibly of neuroectodermal origin. Twenty-one National Wilms' Tumor Study patients with this tumor were treated in the years 1969 through 1978. Mean patient age was 18 months with 16 of the 21 younger than 2 years at diagnosis.

[Experimental study on pharmacokinetics of methotrexate and its metabolite (7-hydroxy-methotrexate) in tissue].

The metabolism of methotrexate was investigated in rabbits with six hours infusion of (3'5'7-3H) methotrexate (50mg/kg). Methotrexate and its metabolites were analyzed by reverse-phase high-pressure liquid chromatography and by counting of radioactivity. 7-Hydroxymethotrexate was found to be the major metabolite in the plasma, urine, bile and tissues of rabbits.

Prognosis in children with Wilms' tumor metastases prior to or following primary treatment: results from the first National Wilms' Tumor Study (NWTS-1).

Survival data from the first National Wilms' Tumor Study were analyzed on 101 patients who relapsed after primary therapy (group I-III) and on 82 patients who presented initially with metastases (group IV). The group I patients had significantly better 3-year survival rates than group II/III patients (64% vs 37%). Histology, relapse site, and time to relapse all showed strong independent effects on survival even in the presence of other variables.